Teva Pharmaceutical Industries Limited Stock TEL AVIV STOCK EXCHANGE
Equities
TEVA
IL0006290147
Pharmaceuticals
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,933 ILa | +0.98% | -0.90% | +29.31% |
Sales 2024 * | 15.86B 6,036B | Sales 2025 * | 16.35B 6,219B | Capitalization | 15.01B 5,710B |
---|---|---|---|---|---|
Net income 2024 * | 1.54B 585B | Net income 2025 * | 1.44B 549B | EV / Sales 2024 * | 1.87 x |
Net Debt 2024 * | 14.62B 5,564B | Net Debt 2025 * | 12.12B 4,611B | EV / Sales 2025 * | 1.66 x |
P/E ratio 2024 * |
10.6
x | P/E ratio 2025 * |
9.91
x | Employees | 35,737 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.71% |
Latest transcript on Teva Pharmaceutical Industries Limited
1 day | +0.98% | ||
1 week | -0.90% | ||
Current month | -4.64% | ||
1 month | -3.01% | ||
3 months | +13.40% | ||
6 months | +48.58% | ||
Current year | +29.31% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 55 | 22-12-31 |
Eli Kalif
DFI | Director of Finance/CFO | 51 | 19-12-21 |
Eric Hughes
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gerald Lieberman
BRD | Director/Board Member | 77 | 15-08-31 |
Janet Vergis
BRD | Director/Board Member | 60 | 20-06-08 |
Sol Barer
CHM | Chairman | 76 | 14-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 4,933 | +0.98% | 1,924,653 |
24-04-24 | 4,885 | +1.14% | 1,186,722 |
24-04-21 | 4,830 | -2.97% | 1,345,230 |
24-04-18 | 4,978 | +0.57% | 736,987 |
24-04-17 | 4,950 | 0.00% | 1,008,493 |
Delayed Quote TEL AVIV STOCK EXCHANGE, April 25, 2024 at 07:24 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.17% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+13.45% | 233B | |
+6.04% | 201B | |
-10.51% | 193B | |
-12.26% | 143B | |
-6.47% | 144B |
- Stock Market
- Equities
- TEVA Stock
- TEVA Stock